Free Republic

New urine-based test looks at 18 genes and was specifically developed to pick out those cancers that need immediate treatment over the slow-growing type. Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment. The test, called MyProstateScore2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. In multiple tests using urine and tissue samples from men with prostate cancer, it successfully identified...

The largest study to date investigating a single invitation to a PSA blood test to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial. After following up for 15 years, there was a small...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, research suggests A new meta-analysis suggests doctors and patients can avoid unnecessary prostate biopsies by combining MRI of the prostate findings with prostate-specific antigen (PSA) density. To doctors, clinically significant prostate cancer (csPCa) is prostate cancer that has a high chance of threatening a patient's life. MRI of the prostate can provide some of this information. Still, a biopsy is traditionally needed to determine how aggressive the cancer cells look. This study tested a new approach: combining MRI-based prostate imaging...

Lloyd Austin underwent an invasive surgical procedure called a prostatectomy for his prostate cancer. He was readmitted to the ICU ward of Walter Reed National Military Medical Center seven days later, on January 1st, due to complications caused by a severe infection. It appears he was septic. He concealed his inability to carry out his duties from Biden, Congress, the Pentagon, and his Deputy Secretary, Dr. Kathleen Hicks. On January 4th, finally becoming aware of Austin’s hospitalization, security adviser Jake Sullivan notified Hicks, who was on vacation in Puerto Rico. Even though Biden continued to back Austin, Austin was already...

An increase in annual cardiorespiratory fitness by 3% or more is linked to a 35% lower risk of developing, although not dying from, prostate cancer, suggests research. They wanted to find out if improvements in cardiorespiratory fitness over time might influence these risks, drawing on a national occupational health profile assessment database. The database collected information on physical activity, lifestyle, perceived health, measurement of body mass and height, and the results of at least two cardiorespiratory fitness tests, measured by peddling on a stationary cycle, for 57,652 men out of a total of 181,673. Annual cardiorespiratory fitness measurements were expressed...

U.S. Defense Secretary Lloyd Austin was recently diagnosed and is being treated for prostate cancer. He is one of the nearly 290,000 American men who will be diagnosed with the condition this year. Nearly all types of cancer have become less deadly over the last 30 years, with one notable exception: advanced-stage prostate cancer, according to a recent report from the American Cancer Society (ACS). “We have had more men diagnosed with more advanced prostate cancer over the last decade,” Dr. Sam S. Chang, the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center, told The Epoch Times in an...

Joe Biden was not informed of the prostate cancer diagnosis of Secretary of Defense Lloyd Austin until today, National Security Council spokesman John Kirby told reporters at Tuesday’s White House press briefing. Kirby said Biden was told of Austin’s illness by White House Chief of Staff Jeff Zients in the morning. A press release earlier Tuesday by doctors treating Austin revealed his cancer diagnosis. ..... Snip..... Biden spoke by phone with Austin on Saturday, reported Politico’s Alex Ward, “Biden held a “cordial conversation” with Austin on Saturday night, per one of the U.S. officials. “The president has complete trust and...

Scientists wanted to investigate the anti-cancer properties of carnosine against cells derived from both primary and metastatic prostate cancer. Carnosine, which can be produced by the body and is also found in meat, has long been advocated for use as an antioxidant to facilitate healthy aging. There have been reports of carnosine being effective against the development of a number of different cancers but this is the first time it has been studied in relation to prostate cancer. The researchers found that carnosine stopped the cells from multiplying and at higher doses even killed cancer from both primary and metastatic...

A study suggests metformin is a drug that could prevent the progression of prostate cancer, but only for tumors with low levels of NKX3.1, which are more likely to develop into aggressive cancers. The researchers found metformin restores cancer-fighting mitochondrial activity that is lost when NKX3.1 levels are low, prevents prostate cancer progression in mice, and is associated with better survival in patients with low-NKX3.1 tumors but not high-NKX3.1 tumors. Papachristodoulou found that when prostate cells are under oxidative stress (as happens during prostate cancer development), NKX3.1 moves into the cells' mitochrondria to reduce stress and protect the cells. If...

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. The question remains as to whether the chemotherapy drug docetaxel, which increases survival in metastatic prostate cancer, can improve the cure rate in these patients. In a new study by investigators from Brigham and Women's Hospital, a meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). Investigators performed a meta-analysis of the RCTs evaluating SOC treatment with radiotherapy and androgen deprivation therapy or with radical...

For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib plus enzalutamide results in improvement in radiographic progression-free survival (rPFS), according to a study. Neeraj Agarwal, M.D. and colleagues conducted a randomized phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy for men with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy from 223 hospitals, cancer centers, and medical centers in 26 countries. Patients were prospectively assessed for homologous recombination repair gene alterations in tumor tissue and randomly assigned to once daily talazoparib or placebo (402 and 203 patients, respectively). The researchers found that...

Medical journals are ranked by prestige, like universities and restaurants, based on criteria that might be more in the eye of the beholder than based on objective criteria. In the medical world, The Lancet and the New England Journal of Medicine are ranked number one and two, respectively, despite both having had to retract shoddy published COVID papers over “data integrity questions.”JAMA, or the Journal of the American Medical Association, is number five on the “best medicine journals” list. It would be reasonable to expect such journals to be publishing cutting-edge medical research papers rather than nonsense better suited for...

Transgender women keep their prostates even after gender-affirming surgery, but the extent to which they remain at risk of prostate cancer has been unclear. Now a first of its kind study led by UC San Francisco has estimated the risk at about 14 cases per 10,000 people. The study drew on 22 years of data from the Veterans Affairs Health System. Although the sample size was necessarily small, it is still the largest study of its kind. It publishes Saturday, April 29, 2023 in the Journal of the American Medical Association (JAMA) and is timed to the annual meeting of...

Transgender women keep their prostates even after gender-affirming surgery, but the extent to which they remain at risk of prostate cancer has been unclear. Now a first of its kind study led by UC San Francisco has estimated the risk at about 14 cases per 10,000 people. The study drew on 22 years of data from the Veterans Affairs Health System. Although the sample size was necessarily small, it is still the largest study of its kind. It publishes Saturday, April 29, 2023 in the Journal of the American Medical Association (JAMA) and is timed to the annual meeting of...

A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates. The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, have been published. For people with metastatic hormone-sensitive prostate cancer, the addition of an androgen receptor blocker with enzalutamide to standard therapy—suppression of testosterone, with or without chemotherapy—led to a 67 percent survival rate after five years. This compares to 57 percent of people who were alive after five years after receiving the standard best practice treatment. "The longer-term analysis showed that the benefit of adding enzalutamide was evident in...

Better Health Publishing — Results from an 18 month phase II clinical trial on the benefits of dietary supplement modified citrus pectin in biochemically relapsed prostate cancer will be presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium, Feb 16-18. Results showed that 18 months of treatment with researched modified citrus pectin (P-MCP) reduced prostate cancer progression, stabilized or decreased PSA, and slowed PSA doubling time (PSADT) without hormonal interference or side effects. These results highlight the clinically relevant benefits of P-MCP in prostate cancer Figure 1: Results from 18 month follow-up on P-MCP in BRPC presented...

Following a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a study suggests. Men who ate a diet rich in fruits, vegetables and whole grains had a 52% lower risk of cancer progressing and a 53% lower risk of recurrence, compared with men who had the lowest amounts of plants in their diet, the researchers found. A plant-based diet may have these benefits because fruits and vegetables contain antioxidants and anti-inflammatory components, as well as dietary fiber that improve glucose control and reduce inflammation, she explained. Also, this diet reduces...

: Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer The authors exposed various prostate cancer cells lines to Ivermectin and found that ivermectin binds to two proteins: FOXA1 and Ku70/Ku80. This leads to the inhibition of androgen receptor (AR), E2F1 expression, and DNA damage repair activity. The cells stopped dividing (G0/G1 cell cycle arrest), experience extensive DNA damage, and die.

Vladimir Putin does have early stage Parkinson's disease and pancreatic cancer, leaked spy documents have alleged in the latest unverified claim about the tyrant's ill health. The Russian leader has been plagued with rumours about his illnesses for months and he has regularly appeared twitching and unsteady in public, sparking hope in Ukraine and the West the despot could soon relinquish power. Claims have been circulating among opposition figures, fuelled by his unexplained absences and his shaky public appearances, that he is battling serious health problems but they have always been rubbished by the Kremlin. -snip- 'Putin is regularly stuffed...

A new study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk disease. "We asked, can we deliver radiation safely and effectively in less time so that our high-risk patients can finish their treatment faster?" said Dr. Niazi. "Hypofractionated treatment for prostate cancer decreases financial toxicity to patients, and it is completed in 25 days instead of the usual 38 to 40 days. That's three...